Oxidative stress in bronchopulmonary disease: Contribution of N-acetylcysteine (NAC);Le stress oxydatif en pathologie broncho-pulmonaire: Apport de la N-acétyl-cystéine (NAC)

Revue de Pneumologie Clinique

Volumn 61, Issue 1 I, 2005, Pages 16-21

  Guerin, J C ^a   Leophonte, P ^a   Lebas, F X ^a   Liard, F ^a   Terrioux, Ph ^a   Boulanger, P ^a  

^a CROIX ROUSSE HOSPITAL   (France)

Author keywords

COPD; N acetylcysteine (NAC); Oxidative stress; Pulmonary fibrosis

Indexed keywords

ACETYLCYSTEINE; PARACETAMOL; TOBACCO SMOKE;

AIR POLLUTION; ANTIOXIDANT ACTIVITY; CELL ACTIVATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG INDICATION; DRUG INTOXICATION; HUMAN; INFLAMMATORY CELL; LIPID PEROXIDATION; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION; LUNG VENTILATION; MACROPHAGE; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; POLYMORPHONUCLEAR CELL; QUALITY OF LIFE; REVIEW;

EID: 15444371281     PISSN: 07618417     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0761-8417(05)84777-7     Document Type: Review

References (56)

1. Rahman I, McNee W. Role of oxidants/antioxidants in smoking-induced lung diseases. Free Radic Biol Med 1996;21:669-81.
2. Repine JE, Bast A, Lankhorst I. Oxidative stress in chronic obstructive pulmonary disease. Oxidative Stress Study Group. Am J Respir Crit Care Med 1997;156:341-57.
3. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153:530-4.
4. Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov SA, Barnes PJ. Exhaled nitric oxide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157(3 Pt 1):998-1002.
5. Eidelman D, Saetta MP, Ghezzo H, Wang NS, Hoidal JR, King M. Cellularity of the alveolar walls in smokers and its relation to alveolar destruction. Functional implications. Am Rev Respir Dis 1990;141:1547-52.
6. Thompson AB, Daughton D, Robbins RA, Ghafouri MA, Oehlerking M, Rennard SI. Intraluminal airway inflammation in chronic bronchitis. Characterization and correlation with clinical parameters. Am Rev Respir Dis 1989;140:1527-37.
7. Selby C, Drost E, Lannan S, Wraith PK, MacNee W. Neutrophil retention in the lungs of patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1991;143:1359-64.
8. Drost EM, Selby C, Bridgeman MM, MacNee W. Decreased leucocyte deformability after acute cigarette smoking in humans. Am Rev Respir Dis 1993;148:1277-83.
9. Postma DS, Renkema TE, Noordhoek JA, Faber H, Sluiter HJ, Kauffman H. Association between nonspecific bronchial hyperreactivity and superoxide anion production by polymorphonuclear leukocytes in chronic air-flow obstruction. Am Rev Respir Dis 1988;137:57-61.
10. Ludwig PW, Hoidal JR. Alterations in leucocyte oxidative metabolism in cigarette smokers. Am Rev Respir Dis 1982;126:977-80.
11. Bridges AB, Scott NA, Parry GJ, Belch JJ. Age, sex, cigarette smoking and indices of free radical activity in healthy humans. Eur J Med 1993;2:205-8.
12. Petruzzelli S, Hietanen E, Bartsch H, Camus AM, Mussi A, Angeletti CA, et al. Pulmonary lipid peroxidation in cigarette smokers and lung cancer patients. Chest 1990;98:930-5.
13. nd, Awad JA, Burk RF, Morrow JD. Effect of oxygen tension on the generation of F2-isoprostanes and malondialdehyde in peroxidizing rat liver microsomes. Biochem Pharmacol 1994;47:1173-7.
14. Morrow JD, Frei B, Longmire AW, Gaziano JM, Lynch SM, Shyr Y, et al. Increase in circulating products of lipid peroxidation (F2-isoprostanes) in smokers. Smoking as a cause of oxidative damage. N Engl J Med 1995;332:1198-203.
15. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD and smokers. Am J Respir Crit Care Med 1996;154:1055-60.
16. Dekhuijzen PN, Aben KKH, Dekker I, Aarts LWP, Van Herwaarden CL, Bast A. Increased exhalation of hydrogen peroxyde in patients with stable and unstable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1997;154:813-6.
17. Greening AP, Lowrie DB. Extracellular release of hydrogen peroxide by human alveolar macrophages: the relationship to cigarette smoking and lower respiratory tract infections. Clin Sci 1983;65:661-4.
18. Dhalla NS, Golfman L, Takeda S, Takeda N, Nagano M. Evidence for the role of oxidative stress in acute ischemic heart disease: a brief review. Can J Cardiol 1999;15:587-93.
19. Koyama H, Geddes DM. Genes, oxidative stress, and the risk of chronic obstructive pulmonary disease. Thorax 1998;53:S10-4.
20. Jones JG, Minty BD, Lawler P, Hulands G, Crawley JC, Veall N. Increased alveolar epithelial permeability in cigarette smokers. Lancet 1980;1(8159):166-8.
21. Jackson JH, Schraufstatter IU, Hyslop PA, Vosbeck K, Sauerheber R, Weitzman SA, et al. Role of oxidants in DNA damage. Hydroxyl radical mediates the synergistic DNA damaging effects of asbestos and cigarette smoke. J Clin Invest 1987;80:1090-5.
22. Barnes PJ, Karin M. Nuclear factor-kappa B: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997;336:1066-71.
23. Evans MD, Pryor WA. Cigarette smoking, emphysema, and damage to alpha 1-proteinase inhibitor. Am J Physiol 1994;266(6 Pt 1):L593-611.
24. Rabe KF, Dent G, Magnussen H. Hydrogen peroxide contracts human airways in vitro: role of epithelium. Am J Physiol 1995;269(3 Pt 1):L332-8.
25. Vanderbist F, Maes P, Neve J. In vitro comparative assessment of the antioxydant activity and nacystelyn against three reactive oxygen species. Arzneimittel-Forschung 1996;46:783-8.
26. Gillissen A, Scharling B, Jaworska M, Bartling A, Rasche K, Schultze-Werninghaus G. Oxidant scavenger function of ambroxol in vitro: a comparison with N-acetylcysteine. Res Exp Med 1997;196:389-98.
27. Aruoma OI, Halliwell B, Hoey BM, Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide and hypochlorous acid. Free Radic Biol Med 1989;6:593-7.
28. Gillissen A, Jaworska M, Orth M, Coffiner M, Maes P, App EM, et al. Nacystelyn, a novel lysine salt of N-acetylcysteine, to augment cellular antioxidant defence in vitro. Respir Med 1997;91:159-68.
29. Moldeus P, Cotgreave IA, Berggren M. Lung protection by a thiol containing antioxydant N-acetylcysteine. Respiration 1986;50:31-42.
30. Cotgreave I, Moldeus P, Schuppe I. The metabolism of N-acetylcysteine by human endothelial cells. Biochem Pharmacol 1991;42:13-6.
31. Russell J, Spickett CM, Reglinski J, Smith WE, McMurray J, Abdullah IB. Alteration of the erythrocyte glutathione redox balance by N-acetylcysteine, captopril and exogenous glutathione. FEBS Lett 1994;347:215-20.
32. Junod AF, Jornot L, Grichting G. Comparative study on the selenium- and N-acetylcysteine-related effects on the toxic action of hyperoxia, paraquat and the enzyme reaction hypoxanthine-xanthine oxidase in cultured endothelial cells. Agents Actions 1987;22:176-83.
33. Bernard GR, Lucht WD, Niedermeyer ME, Snapper JR, Ogletree ML, Brigham KL. Effect of N-acetylcysteine on the pulmonary response to endotoxin in the awake sheep and upon in vitro granulocyte function. J Clin Invest 1984;73:1772-84.
34. Sarnstrand B. Is N-acetylcysteine a free radical sacvenger in vivo? The effect of N-acetylcysteine in oxygen induced lung injury. Eur Respir Rev 1992;2:11-5.
35. Miners JO, Drew R, Birkett DJ. Mechanism of action of paracetamol protective agents in mice in vivo. Biochem Pharmacol 1984;33:2995-3000.
36. Moldeus P, Berggren M, Grafström R. N-acetylcysteine protection against the toxicity of cigarette smoke and cigarette smoke condensates in various tissues and cells in vitro. Eur J Respir Dis 1985;66(Suppl 139):123-9.
37. Jeffery PK, Rogers DF, Ayers MM. Effect of oral acetylcysteine on tobacco smoke-induced secretory cell hyperplasia. Eur J Respir Dis 1985;66(Suppl 139):117-22.
38. Bridges AB. Protectives action of thiols on neutrophil functions. Eur J Respir 1985;66:40-8.
39. Bergstrand H, Bjornson A, Eklund A, Hernbrand R, Larsson K, Linden M. Stimuli-induced superoxide radical generation in vitro by human alveolar macrophages from smokers: modulation by N-acetylcysteine treatment in vivo. J Free Radic Biol Med 1986;2:119-27.
40. Eklund A, Eriksson O, Hakansson L, Larsson K, Ohlsson K, Venge P. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J 1988;1:832-8.
41. Linden M, Wieslander E, Eklund A, Larsson K, Brattsand R. Effects of oral N-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur Respir J 1988;1:645-50.
42. Spies CD, Reinhart K, Witt I, Meier-Hellmann A, Hannemann L, Bredle DL, et al. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit Care Med 1994;22:1738-46.
43. Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol 1998;36:277-85.
44. Perry HE, Shannon MW. Efficacy of oral versus intravenous N-acetylcysteine in acetaminophen overdose: results of an open-label, clinical trial. J Pediatr 1998;132:149-52.
45. Bridgeman MM, Marsden M, Macnee W, Flenley DC, Ryle AP. Cysteine and glutathione concentrations in plasma and bronchoalveolar lavage fluid after treatment with N-acetylcysteine. Thorax 1991;46:39-42.
46. Pacht ER, Timerman AP, Lykens MG, Merola AJ. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 1991;100:1397-403.
47. Suter PM, Domenighetti G, Schaller MD, Laverrière MC, Ritz R, Perret C. N-acetylcysteine enhances recovery from acute lung injury in man. Chest 1994;105:190-4.
48. Meyer A, Buhl R, Kampf S, Magnussen H. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med 1995;152:1055-60.
49. Behr J, Maier K, Degenkolb B, Krombach F, Vogelmeier C. Antioxidative and clinical effects of high-dose N-acetylcysteine in fibrosing alveolitis. Am J Respir Crit Care Med 1997;156:1897-901.
50. Idiopathic Pulmonary Fibrosis International Group Exploring NAC I Annual (IFIGENIA). ERS 2004, Glasgow (Hot topic session n° 257).
51. Kasielski M., Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respir Med 2001;95:448-56.
52. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR. The effect of oral N-acetylcysteine in chronic bronchitis: a quantitative systematic review. Eur Respir J 2000;16:253-62.
53. Reichenberger F, Tamm M. N-acetylcysteine in the therapy of chronic bronchitis. Pneumologie 2002;56:793-7.
54. Dekhuijzen PNR. Antioxidant properties of N-acetylcysteine: their relevance in relation to chronic obstructive pulmonary disease. Eur Respir J 2004;23:629-36.
55. Riise GC, Larsson S, Larsson P, Jeansson S, Andersson BA. The intrabronchial microbial flora in chronic bronchitis patients: a target for N-acetylcysteine therapy? Eur Respir J 1994;7:94-101.
56. Gerrits CMJM, Herings RMC, Leufkens HGM, Lammers JWJ. N-acetylcysteine reduces the risk of re-hospitalisation among patients with chronic obstructive pulmonary disease. Eur Respir J 2003;21:795-8.